Continuing Education Activity
May-Hegglin anomaly (MHA) is a rare autosomal dominant disease characterized by neutrophils with abnormal cytoplasmic inclusions, large platelets, and variable thrombocytopenia. May-Hegglin anomaly is a member of a group of diseases associated with myosin heavy chain single gene defects that represent hereditary forms of macrothrombocytopenia associated with leukocyte inclusions and variable clinical features such as sensorineural hearing loss, presenile cataracts, and renal failure. This group also includes Fechtner syndrome, Sebastian syndrome, and Epstein syndrome. This activity describes the pathophysiology, etiology, presentation and treatment of May-Hegglin anomaly and highlights the role of the interprofessional team in providing care for affected individuals.
Objectives:
Describe the pathophysiology of May-Hegglin anomaly.
Describe the presentation of May-Hegglin anomaly.
Summarize the treatment options for May-Hegglin anomaly.
Explain the importance of optimizing coordination amongst the interprofessional team to enhance the delivery of care to patients with May-Hegglin anomaly.
Access free multiple choice questions on this topic.
Introduction
The May-Hegglin anomaly (MHA) is a rare autosomal dominant disease due to MYH9 gene mutation characterized by neutrophils with abnormal cytoplasmic inclusions, large platelets, and variable thrombocytopenia. It is part of myosin heavy chain (MHC) single gene defect group that also includes Fechtner syndrome, Sebastian syndrome, and Epstein syndrome.[1] All of these entities represent hereditary forms of macrothrombocytopenia associated with leukocyte inclusions (Dohle-like bodies), and variable clinical features of sensorineural hearing loss, presenile (early) cataracts, and renal failure.
Etiology
The mutated MYH9 gene is present on chromosome 22q12–13 and encodes the nonmuscle myosin heavy chain class IIA (NMMHC-IIA).[2] At least 33 mutations in the MYH9 gene have been identified. NMMHC-IIA is a cytoplasmic protein that is present in many tissues including platelets. The mutation causes abnormal production of NMMHC-IIA. This leads to macrothrombocytopenia secondary to defective megakaryocytic maturation and fragmentation. The crescent shaped Dohle-like inclusion bodies are precipitates of MHC within the cytoplasm of eosinophils, neutrophils, and monocytes. Neutrophil and platelet function is considered to be normal.
Epidemiology
May Hegglin anomaly is a rare disease with a few reported cases. It was first described by german doctor May in 1909 and then in 1945 by doctor Hegglin from Switzerland. The exact worldwide incidence of this anomaly is unknown, but there are fewer than a hundred cases reported in the literature.
History and Physical
Physical findings may be normal. About half of the reported patients are asymptomatic, and the other half have platelet counts < 50 K/uL and abnormal bleeding. Characteristic features of MHA include epistaxis, easy bruising, gingival bleeding, menorrhagia and excessive postoperative bleeding. The bleeding symptoms depend on the degree of thrombocytopenia. They vary from generally mild not requiring specific treatment to rare, severe bleeding episodes after surgical procedures that need blood transfusions. Fatal bleeding has not been reported.
Evaluation
Review of complete blood count (CBC) and careful evaluation of peripheral blood smear along with a detailed family history of bleeding diathesis are key for establishing the diagnosis of MHA.
Peripheral Smear
The platelet count ranges from 40–80 K/uL to normal values. Characteristic morphological findings of white blood cells and platelets are present on peripheral blood smear. Cytoplasmic inclusions resembling Dohle bodies are seen in neutrophils, but also in monocytes, eosinophils, and basophils. The inclusions appear pale blue on Wright–Giemsa stain, are large and spindle shaped. The inclusion bodies are not seen in platelets. Platelets appear larger in size with the presence of large and giant forms. The presence of macrothrombocytes in some patients can often lead to underestimation of platelet count by automated analyzers. In such cases, platelet count can be better estimated based on a careful morphologic evaluation of the peripheral blood smear. On electron microscopy, the platelets have abnormal lentiform shape due to the presence of increased amount of abnormally organized microtubules (parallel order of filaments in the inclusions).
Bone Marrow Exam
Both the number and morphology of megakaryocytes are normal on bone marrow examination. There is no evidence of dysplasia. The abnormal megakaryocytic fragmentation is believed to be the cause of the decreased platelet count.
Platelet Aggregation Studies
The normal pattern of platelet aggregation and ATP secretion are seen in most cases of MHA.
Additional Findings
Bleeding time is prolonged in proportion to the degree of thrombocytopenia. The life span of platelets is usually normal. Immunofluorescence study of neutrophil NMMHC-IIA can be helpful for diagnosis of MHA in patients without leukocyte inclusion bodies. The presence of inclusion bodies in leukocytes helps to distinguish MHA from immune-mediated thrombocytopenia. Genetic studies for MYH9 gene mutation can confirm the diagnosis of MHA in uncertain cases. A comprehensive molecular evaluation includes a screening of 40 exons. It is hypothesized that genetic assessment can evaluate the risk of development of cataracts, deafness and kidney disease but this is debatable.
Differential Diagnosis
Epstein syndrome lacks leukocyte inclusions. If Alport syndrome-like features (deafness, cataracts, and nephritis) are suspected, an audiogram, renal function testing (creatinine, blood urea nitrogen, proteinuria) and ophthalmologic examination should be performed. Both Epstein and Fechtner syndromes have clinical characteristics similar to Alport syndrome. Ultrastructural features of leukocyte inclusion bodies differentiate Sebastian syndrome from MHA. MHA does not have limiting membrane on electron microscopy and shows ribosomes clusters oriented along the axis of thin parallel filaments. In contrast, Sebastian syndrome has ribosomes but without parallel filaments depolymerized ribosomes.
Treatment / Management
Most patients do not have clinically significant bleeding problems and are discovered incidentally. These patients require no specific treatment. In rare cases of severe bleeding, platelet transfusions may be necessary. Prophylactic preoperative platelet transfusion may be warranted, and a hematologist should be consulted before surgery. Preoperative Desmopressin can be administered in patients requiring craniotomy in order to avoid any bleeding complications or platelet transfusion.[3] Administration of corticosteroids, immunosuppressive agents or splenectomy is not indicated.
Pearls and Other Issues
A special circumstance when MHA should be considered is pregnancy.[4] MHA is a rare cause of thrombocytopenia in pregnancy. While some women are diagnosed with MHA before pregnancy, in other patients the disease is first recognized during pregnancy when thrombocytopenia is picked up on a routine CBC count. Often a majority of these pregnant women are initially believed to have immune-mediated thrombocytopenia (ITP) not responding to treatment. The diagnosis of MHA should, however, be considered when platelet count does not improve despite treatment for ITP. Early recognition of MHA during pregnancy can be challenging, but it ensures the most favorable outcome for the mother and the neonate. There is very limited data in the literature on the clinical course and outcome of MHA in pregnant women. Both the mother and the newborn are at risk of bleeding complications. The fetus has 50% chance of inheriting the disease. A multidisciplinary approach is recommended for the management of pregnant women with MHA, including obstetrician, hematologist, and anesthetist. This will minimize maternal and neonatal bleeding risks and secure the best treatment options.
Enhancing Healthcare Team Outcomes
MHA is best managed by an interprofessional team that includes hematology nurses. The condition does not always require treatment. MHA can often be misdiagnosed as idiopathic thrombocytopenic purpura (ITP) if a thorough evaluation of blood smear and a detailed bleeding history including family history is not taken.[5] Genetic studies may be required to make an accurate diagnosis. It is essential not to misdiagnose MHA as this can lead to unnecessary diagnostic studies, such as bone marrow aspiration and biopsy and even misdirected therapeutic intervention with corticosteroids, immunosuppressive agents, and splenectomy.
References
- 1.
Hsia CC, Xenocostas A. May-Hegglin anomaly.
Blood. 2012 Jan 12;119(2):328. [
PubMed: 22351964]
- 2.
Fatima S. May hegglin anomaly: rare entity with review of literature.
Indian J Hematol Blood Transfus. 2012 Mar;28(1):58-60. [
PMC free article: PMC3311968] [
PubMed: 23450942]
- 3.
Sehbai AS, Abraham J, Brown VK. Perioperative management of a patient with May-Hegglin anomaly requiring craniotomy.
Am J Hematol. 2005 Aug;79(4):303-8. [
PubMed: 16044442]
- 4.
Hussein BA, Gomez K, Kadir RA. May-Hegglin anomaly and pregnancy: a systematic review.
Blood Coagul Fibrinolysis. 2013 Jul;24(5):554-61. [
PubMed: 23811802]
- 5.
Sung CC, Lin SH, Chao TK, Chen YC. R1933X mutation in the MYH9 gene in May-Hegglin anomaly mimicking idiopathic thrombocytopenic purpura.
J Formos Med Assoc. 2014 Jan;113(1):56-9. [
PubMed: 23759689]
Disclosure: Ramona Untanu declares no relevant financial relationships with ineligible companies.
Disclosure: Neerja Vajpayee declares no relevant financial relationships with ineligible companies.
